Our focus

The AEON difference

Injectable neurotoxins are renowned for their versatility, with numerous aesthetic and therapeutic applications. However, we have yet to fully explore their potential to treat a wide range of medical conditions. At AEON, we are solely focused on and committed to developing and delivering proven treatments to the people who need them most.

close up of man's neck -aeon difference

ABP-450: one molecule, myriad possibilities

Our lead candidate, ABP-450 (prabotulinumtoxinA) injection, has demonstrated the ability to significantly reduce symptoms and improve function in patients with chronic neuromuscular conditions.

ABP-450 is a 900-kDa botulinum toxin type A complex that has a proven safety profile. When injected at therapeutic doses, ABP-450 works by blocking the release of acetylcholine, a neurotransmitter that signals muscles to contract.1 By reducing nerve and muscle activity in strategic areas, ABP-450 may help alleviate the symptoms of migraines, cervical dystonia, and other disorders.

With targeted nerve and muscle guidance, proprietary injection methods, exploration of new treatment areas, and a path to market, we believe that we can provide the optimal clinical performance of ABP-450 in the medical conditions we address.

ABP-450 key highlights

globe - icon

Same botulinum toxin complex that has been approved in the United States, the European Union, and Canada for aesthetic use2

price tag - pricing - icon

Sole focus on therapeutic treatment in medical conditions means greater pricing flexibility without being tied to aesthetics

checkmark - approved - icon

Manufacturing site has been inspected and approved by the US Food and Drug Administration, the European Medicines Agency, and Health Canada


To learn more about our indications in development, visit our pipeline page.

Scroll to Top